



## EAST LANCASHIRE HEALTH ECONOMY MEDICINES MANAGEMENT BOARD

### MINUTES OF THE EMAIL MEETING MAR-APRIL 2020 HELD IN WEEK ENDING 22<sup>ND</sup> MAY 2020

#### RESPONSES RECEIVED FROM:

Mr V Goodey (VG)	Assistant Director of Pharmacy, Clin Service ELHT
Dr S Jackson (SJ)	Clinical Commissioning Group MM Lead, GP EL
Mrs C Woffindin (CW)	Medicines Information Manager, ELHT
Dr L Rogan (LR)	Strategic Director of Medicines, Research and Clinical Effectiveness NHS EL CCG
Mrs C Dugdale (CD)	Meds Management Pharmacist NHS BwD CCG

#### 2020/025: APOLOGIES (No Response):

Mr N Fletcher (NF)	Director of Pharmacy ELHT
Dr D Gavan (DG)	Consultant Radiologist ELHT
Mr J Vaughan (JV)	Commissioning Support Pharmacist NHS EL/BwD
Dr T McKenzie (TM)	GP EL CCG
Mr A Gray (AG)	Clinical Pharmacist, ELHT
Dr N Amir (NA)	Consultant Microbiologist, ELHT
Mr U Akram	Pharmacist, Lancashire Care Foundation Trust

#### 2020/026: DECLARATION OF INTEREST

None declared – relevant to agenda items.

#### 2020/027: MINUTES OF FEBRUARY MEETING:

Accepted as a correct record.

#### 2020/028: MATTERS ARISING:

**2019/178: LSCMMG Recommendations (From Nov LSCMMG) - Rheumatoid Arthritis High Cost drugs Pathway – updated – biosimilar names now included and can be uploaded to website.**

**2020/020: Formulary Updates - Phenobarbitone liquid 50mg/5mL, Chloral hydrate liquid 500mg/5mL, Chlorothiazide liquid 250mg/5mL, Sodium bicarbonate 1mmol/mL oral solution – Referrals are going to IMOT . The medicines can remain with a red traffic light.**

## **2020/029: LSCMMG Recommendations (From Feb LSCMMG)**

**Asthma Treatment Guideline for Children** - Accepted as written for ELHE.

**Azathioprine & Mercaptopurine Shared Care Guideline** - Accepted as written for ELHE.

**Antipsychotics Shared Care Guideline** - Accepted as written for ELHE

**Testosterone Shared Care Guidelines – updated** – Concerns raised re recommended PSA monitoring (but it is in accordance with SPC for testosterone). Accepted as written for ELHE.

**L & SC Self-care and Access to OTC Medicines template policy – updated** – Acknowledged.

## **2020/030: FORMULARY UPDATES**

**Ondansetron MHRA information** – amend traffic light to Red for hyperemesis in light of MHRS information in pregnancy, remain green for other formulary indications.

**Traffic Light: RED - hyperemesis**

**Traffic Light: GREEN - nausea/vomiting**

**Ingenol mebutate (Picato®)** – discontinued – remove from formulary.

**Famotidine** – defer to next meeting for discussion.

**Resolved: Formulary to be updated as above**

## **2020/031: NICE RECOMMENDATIONS (from Feb)**

Sotagliflozin with insulin for treating type 1 diabetes [TA622] is recommended as an option by NICE. Approved in line with NICE. (Not yet available in the NHS)  
CCG Commissioned (Not yet available in the NHS) **Traffic Light: GREEN**

Patiromer for treating hyperkalaemia (TA623) is recommended as an option by NICE. Approved in line with NICE.  
CCG Commissioned **Traffic Light: RED/AMBER**

Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis (TA624) is recommended as an option by NICE. Approved in line with NICE.  
NHS England Commissioned **Traffic Light: RED**

Dapagliflozin with insulin for treating type 1 diabetes (TA597 updated) is recommended as an option by NICE. Approved in line with NICE.  
CCG Commissioned **Traffic Light: GREEN**

## **2020/032: NICE RECOMMENDATIONS (from Mar & April)**

Recombinant human parathyroid hormone for treating hypoparathyroidism (terminated appraisal) (TA625) **Traffic Light: BLACK**

Lenalidomide with rituximab for previously treated follicular lymphoma (TA627) is recommended as an option by NICE. Approved in line with NICE.  
NHS England Commissioned **Traffic Light: RED**

## **2020/033: Daratumumab for Multiple Myeloma – unlicensed subcutaneous administration**

The NHS England Commercial Medicines Team and the Cancer Programme of Care team recommend the unlicensed subcutaneous administration of daratumumab for multiple myeloma as an option during the pandemic. It will be supplied free of charge by the company.

Accepted for use if required in ELHE.

## **STANDING ITEMS**

### **2020/034: FOR ACTION/INFORMATION: LANCASHIRE & SOUTH CUMBRIA MEDICINES MANAGEMENT GROUP (LSCMMG) MINUTES - February 2020**

Minutes acknowledged

### **2020/035: FOR ACTION/INFORMATION: LSCNHSFT Drug & Therapeutics Committee Minutes Jan 2020**

Minutes acknowledged

### **2020/036: FOR ACTION/INFORMATION: ANTIMICROBIAL STEWARDSHIP COMMITTEE MINUTES – Jan 2020**

Minutes acknowledged

**DATE OF NEXT MEETING – via ‘Teams’ – to be arranged**

**ACTION SHEET FROM  
EAST LANCASHIRE HEALTH ECONOMY  
MEDICINES MANAGEMENT BOARD**

**WEDNESDAY March - April 2020**

<b>MINUTE NUMBER</b>	<b>DESCRIPTION</b>	<b>ACTION</b>	<b>DATE</b>
<b>2019/131</b>	<b>Treatment Of Vitamin B12 Deficiency Draft</b> – pathway to be developed	LR/JV	Feb 20
<b>2020/015</b>	<b>New Product request – Relvar Ellipta® &amp; Anoro Ellipta®</b> - Discuss with CCG leads and bring back to ELMMB if further discussion required	JV	Mar 20
<b>2020/020</b>	<b>Formulary Updates – Ranolazine &amp; Ivabradine</b> – Hot Topic to support GP prescribing to be produced with assistance from Dr Singh	JV	Apr 20